[Code of Federal Regulations]
[Title 40, Volume 31]
[Revised as of July 1, 2006]
From the U.S. Government Printing Office via GPO Access
[CITE: 40CFR799.9537]
[Page 429-435]
TITLE 40--PROTECTION OF ENVIRONMENT
CHAPTER I--ENVIRONMENTAL PROTECTION AGENCY (CONTINUED)
PART 799_IDENTIFICATION OF SPECIFIC CHEMICAL SUBSTANCE AND MIXTURE
TESTING REQUIREMENTS--Table of Contents
Subpart H_Health Effects Test Guidelines
Sec. 799.9537 TSCA in vitro mammalian chromosome aberration test.
(a) Scope--(1) Applicability. This section is intended to meet
testing requirements under section 4 of the Toxic Substances Control Act
(TSCA) (15 U.S.C. 2601).
(2) Background. The source material used in developing this TSCA
test
[[Page 430]]
guideline is the Office of Prevention, Pesticides, and Toxic Substances
(OPPTS) harmonized test guideline 870.5375 (August 1998, final
guidelines). The source is available at the address in paragraph (i) of
this section.
(b) Purpose. (1) The purpose of the in vitro chromosome aberration
test is to identify agents that cause structural chromosome aberrations
in cultured mammalian cells (see paragraphs (i)(1), (i)(2), and (i)(3)
of this section). Structural aberrations may be of two types, chromosome
or chromatid. With the majority of chemical mutagens, induced
aberrations are of the chromatid type, but chromosome-type aberrations
also occur. An increase in polyploidy may indicate that a chemical has
the potential to induce numerical aberrations. However, this guideline
is not designed to measure numerical aberrations and is not routinely
used for that purpose. Chromosome mutations and related events are the
cause of many human genetic diseases and there is substantial evidence
that chromosome mutations and related events causing alterations in
oncogenes and tumour-suppressor genes of somatic cells are involved in
cancer induction in humans and experimental animals.
(2) The in vitro chromosome aberration test may employ cultures of
established cell lines, cell strains or primary cell cultures. The cells
used are selected on the basis of growth ability in culture, stability
of the karyotype, chromosome number, chromosome diversity, and
spontaneous frequency of chromosome aberrations.
(c) Definitions. The definitions in section 3 of TSCA and in 40 CFR
Part 792--Good Laboratory Practice Standards apply to this test
guideline. The following definitions also apply to this test guideline.
Chromatid-type aberration is structural chromosome damage expressed
as breakage of single chromatids or breakage and reunion between
chromatids.
Chromosome-type aberration is structural chromosome damage expressed
as breakage, or breakage and reunion, of both chromatids at an identical
site.
Endoreduplication is a process in which after an S period of DNA
replication, the nucleus does not go into mitosis but starts another S
period. The result is chromosomes with 4, 8, 16,...chromatids.
Gap is an achromatic lesion smaller than the width of one chromatid,
and with minimum misalignment of the chromatid(s).
Mitotic index is the ratio of cells in metaphase divided by the
total number of cells observed in a population of cells; an indication
of the degree of proliferation of that population.
Numerical aberration is a change in the number of chromosomes from
the normal number characteristic of the cells utilized.
Polyploidy is a multiple of the haploid chromosome number (n) other
than the diploid number (i.e., 3n, 4n, and so on).
Structural aberration is a change in chromosome structure detectable
by microscopic examination of the metaphase stage of cell division,
observed as deletions and fragments, intrachanges, and interchanges.
(d) Initial considerations. (1) Tests conducted in vitro generally
require the use of an exogenous source of metabolic activation. This
metabolic activation system cannot mimic entirely the mammalian in vivo
conditions. Care should be taken to avoid conditions which would lead to
positive results which do not reflect intrinsic mutagenicity and may
arise from changes in pH, osmolality, or high levels of cytotoxicity
(the test techniques described in the references under paragraphs (i)(4)
and (i)(5) of this section may be used).
(2) This test is used to screen for possible mammalian mutagens and
carcinogens. Many compounds that are positive in this test are mammalian
carcinogens; however, there is not a perfect correlation between this
test and carcinogenicity. Correlation is dependent on chemical class and
there is increasing evidence that there are carcinogens that are not
detected by this test because they appear to act through mechanisms
other than direct DNA damage.
(e) Principle of the test method. Cell cultures are exposed to the
test substance both with and without metabolic activation. At
predetermined intervals after exposure of cell cultures
[[Page 431]]
to the test substance, they are treated with a metaphase-arresting
substance (e.g., Colcemid [reg] or colchicine), harvested,
stained, and metaphase cells are analysed microscopically for the
presence of chromosome aberrations.
(f) Description of the method--(1) Preparations--(i) Cells. A
variety of cell lines, strains, or primary cell cultures, including
human cells, may be used (e.g., Chinese hamster fibroblasts, human, or
other mammalian peripheral blood lymphocytes).
(ii) Media and culture conditions. Appropriate culture media, and
incubation conditions (culture vessels, CO2 concentration, temperature
and humidity) must be used in maintaining cultures. Established cell
lines and strains must be checked routinely for stability in the modal
chromosome number and the absence of Mycoplasma contamination and should
not be used if contaminated. The normal cell-cycle time for the cells
and culture conditions used should be known.
(iii) Preparation of cultures--(A) Established cell lines and
strains. Cells are propagated from stock cultures, seeded in culture
medium at a density such that the cultures will not reach confluency
before the time of harvest, and incubated at 37 [deg]C.
(B) Lymphocytes. Whole blood treated with an anti-coagulant (e.g.,
heparin) or separated lymphocytes obtained from healthy subjects are
added to culture medium containing a mitogen (e.g., phytohemagglutinin)
and incubated at 37 [deg]C.
(iv) Metabolic activation. Cells must be exposed to the test
substance both in the presence and absence of an appropriate metabolic
activation system. The most commonly used system is a co-factor-
supplemented post-mitochondrial fraction (S9) prepared from the livers
of rodents treated with enzyme-inducing agents such as Aroclor 1254 (the
test techniques described in the references under paragraphs (i)(6),
(i)(7), (8)(i), and (i)(9) of this section may be used), or a mixture of
phenobarbitone and [beta]-naphthoflavone (the test techniques described
in the references under paragraphs (i)(10), (i)(11), and (i)(12) of this
section may be used). The post-mitochondrial fraction is usually used at
concentrations in the range from 1-10% v/v in the final test medium. The
condition of a metabolic activation system may depend upon the class of
chemical being tested. In some cases, it may be appropriate to utilize
more than one concentration of post-mitochondrial fraction. A number of
developments, including the construction of genetically engineered cell
lines expressing specific activating enzymes, may provide the potential
for endogenous activation. The choice of the cell lines used should be
scientifically justified (e.g., by the relevance of the cytochrome P450
isoenzyme for the metabolism of the test substance).
(v) Test substance/preparation. Solid test substances should be
dissolved or suspended in appropriate solvents or vehicles and diluted,
if appropriate, prior to treatment of the cells. Liquid test substances
may be added directly to the test systems and/or diluted prior to
treatment. Fresh preparations of the test substance should be employed
unless stability data demonstrate the acceptability of storage.
(2) Test conditions--(i) Solvent/vehicle. The solvent/vehicle should
not be suspected of chemical reaction with the test substance and must
be compatible with the survival of the cells and the S9 activity. If
other than well-known solvent/vehicles are used, their inclusion should
be supported by data indicating their compatibility. It is recommended
that wherever possible, the use of an aqueous solvent/vehicle be
considered first. When testing water-unstable substances, the organic
solvents used should be free of water. Water can be removed by adding a
molecular sieve.
(ii) Exposure concentrations. (A) Among the criteria to be
considered when determining the highest concentration are cytotoxicity,
solubility in the test system, and changes in pH or osmolality.
(B) Cytotoxicity should be determined with and without metabolic
activation in the main experiment using an appropriate indication of
cell integrity and growth, such as degree of confluency, viable cell
counts, or mitotic index. It may be useful to determine cytotoxicity and
solubility in a preliminary experiment.
[[Page 432]]
(C) At least three analyzable concentrations should be used. Where
cytotoxicity occurs, these concentrations should cover a range from the
maximum to little or no toxicity; this will usually mean that the
concentrations should be separated by no more than a factor between 2
and [radic]10. At the time of harvesting, the highest concentration
should show a significant reduction in degree of confluency, cell count
or mitotic index, (all greater than 50%). The mitotic index is only an
indirect measure of cytotoxic/cytostatic effects and depends on the time
after treatment. However, the mitotic index is acceptable for suspension
cultures in which other toxicity measurements may be cumbersome and
impractical. Information on cell-cycle kinetics, such as average
generation time (AGT), could be used as supplementary information. AGT,
however, is an overall average that does not always reveal the existence
of delayed subpopulations, and even slight increases in average
generation time can be associated with very substantial delay in the
time of optimal yield of aberrations. For relatively non-cytotoxic
compounds the maximum concentration should be 5 [micro]g/ml, 5mg/ml, or
0.01M, whichever is the lowest.
(D) For relatively insoluble substances that are not toxic at
concentrations lower than the insoluble concentration, the highest dose
used should be a concentration above the limit of solubility in the
final culture medium at the end of the treatment period. In some cases
(e.g., when toxicity occurs only at higher than the lowest insoluble
concentration) it is advisable to test at more than one concentration
with visible precipitation. It may be useful to assess solubility at the
beginning and the end of the treatment, as solubility can change during
the course of exposure in the test system due to presence of cells, S9,
serum etc. Insolubility can be detected by using the unaided eye. The
precipitate should not interfere with the scoring.
(iii) Controls. (A) Concurrent positive and negative (solvent or
vehicle) controls both with and without metabolic activation must be
included in each experiment. When metabolic activation is used, the
positive control chemical must be the one that requires activation to
give a mutagenic response.
(B) Positive controls must employ a known clastogen at exposure
levels expected to give a reproducible and detectable increase over
background which demonstrates the sensitivity of the test system.
Positive control concentrations should be chosen so that the effects are
clear but do not immediately reveal the identity of the coded slides to
the reader. Examples of positive-control substances include:
------------------------------------------------------------------------
Metabolic activation condition Chemical CAS number
------------------------------------------------------------------------
Absence of exogenous metabolic Methyl [66-27-3]
activation. methanesulfonate.
Ethyl [62-50-0]
methanesulfonate.
Ethylnitrosourea.. [759-73-9]
Mitomycin C....... [50-07-7]
4-Nitroquinoline-N- [56-57-5]
Oxide.
Presence of exogenous metabolic Benzo(a)pyrene.... [50-32-8]
activation.
Cyclophosphamide.. [50-18-0]
(monohydrate)..... ([6055-19-2])
------------------------------------------------------------------------
(C) Other appropriate positive control substances may be used. The
use of chemical class-related positive-control chemicals may be
considered, when available.
(D) Negative controls, consisting of solvent or vehicle alone in the
treatment medium, and treated in the same way as the treatment cultures,
must be included for every harvest time. In addition, untreated controls
should also be used unless there are historical-control data
demonstrating that no deleterious or mutagenic effects are induced by
the chosen solvent.
(g) Procedure--(1) Treatment with test substance. (i) Proliferating
cells are treated with the test substance in the presence and absence of
a metabolic-activation system. Treatment of lymphocytes should commence
at about 48 hours after mitogenic stimulation.
(ii) Duplicate cultures must be used at each concentration, and are
strongly recommended for negative/solvent control cultures. Where
minimal variation between duplicate cultures can be demonstrated (the
test techniques described in the references under paragraphs (i)(13) and
(i)(14) of this section
[[Page 433]]
may be used), from historical data, it may be acceptable for single
cultures to be used at each concentration.
(iii) Gaseous or volatile substances should be tested by appropriate
methods, such as in sealed culture vessels (the test techniques
described in the references under paragraphs (i)(15) and (i)(16) of this
section may be used).
(2) Culture harvest time. In the first experiment, cells should be
exposed to the test substance both with and without metabolic activation
for 3-6 hours, and sampled at a time equivalent to about 1.5 normal
cell-cycle length after the beginning of treatment (the test techniques
described in the references under paragraph (i)(12) of this section may
be used). If this protocol gives negative results both with and without
activation, an additional experiment without activation should be done,
with continuous treatment until sampling at a time equivalent to about
1.5 normal cell-cycle lengths. Certain chemicals may be more readily
detected by treatment/sampling times longer than 1.5 cycle lengths.
Negative results with metabolic activation need to be confirmed on a
case-by-case basis. In those cases where confirmation of negative
results is not considered necessary, justification should be provided.
(3) Chromosome preparation. Cell cultures must be treated with
Colcemid [reg] or colchicine usually for 1 to 3 hours prior
to harvesting. Each cell culture must be harvested and processed
separately for the preparation of chromosomes. Chromosome preparation
involves hypotonic treatment of the cells, fixation and staining.
(4) Analysis. (i) All slides, including those of positive and
negative controls, must be independently coded before microscopic
analysis. Since fixation procedures often result in the breakage of a
proportion of metaphase cells with loss of chromosomes, the cells scored
must therefore contain a number of centromeres equal to the modal number
2 for all cell types. At least 200 well-spread
metaphases should be scored per concentration and control equally
divided amongst the duplicates, if applicable. This number can be
reduced when high numbers of aberrations are observed.
(ii) Though the purpose of the test is to detect structural
chromosome aberrations, it is important to record polyploidy and
endoreduplication when these events are seen.
(h) Data and reporting--(1) Treatment of results. (i) The
experimental unit is the cell, and therefore the percentage of cells
with structural chromosome aberration(s) should be evaluated. Different
types of structural chromosome aberrations must be listed with their
numbers and frequencies for experimental and control cultures. Gaps are
recorded separately and reported but generally not included in the total
aberration frequency.
(ii) Concurrent measures of cytotoxicity for all treated and
negative control cultures in the main aberration experiment(s) should
also be recorded.
(iii) Individual culture data should be provided. Additionally, all
data should be summarized in tabular form.
(iv) There is no requirement for verification of a clear positive
response. Equivocal results should be clarified by further testing
preferably using modification of experimental conditions. The need to
confirm negative results has been discussed in paragraph (g)(2) of this
section. Modification of study parameters to extend the range of
conditions assessed should be considered in follow-up experiments. Study
parameters that might be modified include the concentration spacing and
the metabolic activation conditions.
(2) Evaluation and interpretation of results. (i) There are several
criteria for determining a positive result, such as a concentration-
related increase or a reproducible increase in the number of cells with
chromosome aberrations. Biological relevance of the results should be
considered first. Statistical methods may be used as an aid in
evaluating the test results (see paragraphs (i)(3) and (i)(13) of this
section). Statistical significance should not be the only determining
factor for a positive response.
(ii) An increase in the number of polyploid cells may indicate that
the test substance has the potential to inhibit mitotic processes and to
induce numerical chromosome aberrations. An increase in the number of
cells with
[[Page 434]]
endoreduplicated chromosomes may indicate that the test substance has
the potential to inhibit cell-cycle progression (the test techniques
described in the references under paragraphs (i)(17) and (i)(18) of this
section may be used).
(iii) A test substance for which the results do not meet the
criteria in paragraphs (h)(2)(i) and (h)(2)(ii) of this section is
considered nonmutagenic in this system.
(iv) Although most experiments will give clearly positive or
negative results, in rare cases the data set will preclude making a
definite judgement about the activity of the test substance. Results may
remain equivocal or questionable regardless of the number of times the
experiment is repeated.
(v) Positive results from the in vitro chromosome aberration test
indicate that the test substance induces structural chromosome
aberrations in cultured mammalian somatic cells. Negative results
indicate that, under the test conditions, the test substance does not
induce chromosome aberrations in cultured mammalian somatic cells.
(3) Test report. The test report must include the following
information.
(i) Test substance.
(A) Identification data and CAS no., if known.
(B) Physical nature and purity.
(C) Physicochemical properties relevant to the conduct of the study.
(D) Stability of the test substance, if known.
(ii) Solvent/vehicle.
(A) Justification for choice of solvent/vehicle.
(B) Solubility and stability of the test substance in solvent/
vehicle, if known.
(iii) Cells.
(A) Type and source of cells.
(B) Karyotype features and suitability of the cell type used.
(C) Absence of Mycoplasma, if applicable.
(D) Information on cell-cycle length.
(E) Sex of blood donors, whole blood or separated lymphocytes,
mitogen used.
(F) Number of passages, if applicable.
(G) Methods for maintenance of cell cultures if applicable.
(H) Modal number of chromosomes.
(iv) Test conditions.
(A) Identity of metaphase arresting substance, its concentration and
duration of cell exposure.
(B) Rationale for selection of concentrations and number of cultures
including, e.g., cytotoxicity data and solubility limitations, if
available.
(C) Composition of media, CO2 concentration if applicable.
(D) Concentration of test substance.
(E) Volume of vehicle and test substance added.
(F) Incubation temperature.
(G) Incubation time.
(H) Duration of treatment.
(I) Cell density at seeding, if appropriate.
(J) Type and composition of metabolic activation system, including
acceptability criteria.
(K) Positive and negative controls.
(L) Methods of slide preparation.
(M) Criteria for scoring aberrations.
(N) Number of metaphases analyzed.
(O) Methods for the measurements of toxicity.
(P) Criteria for considering studies as positive, negative or
equivocal.
(v) Results.
(A) Signs of toxicity, e.g., degree of confluency, cell-cycle data,
cell counts, mitotic index.
(B) Signs of precipitation.
(C) Data on pH and osmolality of the treatment medium, if
determined.
(D) Definition for aberrations, including gaps.
(E) Number of cells with chromosome aberrations and type of
chromosome aberrations given separately for each treated and control
culture.
(F) Changes in ploidy if seen.
(G) Dose-response relationship, where possible.
(H) Statistical analyses, if any.
(I) Concurrent negative (solvent/vehicle) and positive control data.
(J) Historical negative (solvent/vehicle) and positive control data,
with ranges, means and standard deviations.
(vi) Discussion of the results.
(vii) Conclusion.
(i) References. For additional background information on this test
guideline, the following references should be consulte. These references
are available for inspection at the TSCA Nonconfidential Information
Center, Rm.
[[Page 435]]
NE-B607, Environmental Protection Agency, 401 M St., SW., Washington,
DC, 12 noon to 4 p.m., Monday through Friday, except legal holidays.
(1) Evans, H.J. Cytological Methods for Detecting Chemical Mutagens.
Chemical Mutagens, Principles and Methods for their Detection, Vol. 4,
Hollaender, A. Ed. Plenum Press, New York and London, pp. 1-29 (1976).
(2) Ishidate, M. Jr. and Sofuni, T. The In Vitro Chromosomal
Aberration Test Using Chinese Hamster Lung (CHL) Fibroblast Cells in
Culture. Progress in Mutation Research, Vol. 5, Ashby, J. et al., Eds.
Elsevier Science Publishers, Amsterdam-New York-Oxford, pp. 427-432
(1985).
(3) Galloway, S.M. et al. Chromosome aberration and sister chromatid
exchanges in Chinese hamster ovary cells: Evaluation of 108 chemicals.
Environmental and Molecular Mutagenesis 10 (suppl. 10), 1-175 (1987).
(4) Scott, D. et al. Genotoxicity under Extreme Culture Conditions.
A report from ICPEMC Task Group 9. Mutation Research 257, 147-204
(1991).
(5) Morita, T. et al. Clastogenicity of Low pH toVarious Cultured
Mammalian Cells. Mutation Research 268, 297-305 (1992).
(6) Ames, B.N., McCann, J. and Yamasaki, E. Methods for Detecting
Carcinogens and Mutagens with the Salmonella/Mammalian Microsome
Mutagenicity Test. Mutation Research 31, 347-364 (1975).
(7) Maron, D.M. and Ames, B.N. Revised Methods for the Salmonella
Mutagenicity Test. Mutation Research 113, 173-215 (1983).
(8) Natarajan, A.T. et al. Cytogenetic Effects of Mutagens/
Carcinogens after Activation in a Microsomal System In Vitro, I.
Induction of Chromosome Aberrations and Sister Chromatid Exchanges by
Diethylnitrosamine (DEN) and Dimethylnitrosamine (DMN) in CHO Cells in
the Presence of Rat-Liver Microsomes. Mutation Research 37, 83-90
(1976).
(9) Matsuoka, A., Hayashi, M. and Ishidate, M., Jr. Chromosomal
Aberration Tests on 29 Chemicals Combined with S9 Mix In Vitro. Mutation
Research 66, 277-290 (1979).
(10) Elliot, B.M. et al. Report of UK Environmental Mutagen Society
Working Party. Alternatives to Aroclor 1254-induced S9 in In Vitro
Genotoxicity Assays. Mutagenesis 7, 175-177 (1992).
(11) Matsushima, T. et al. A Safe Substitute for Polychlorinated
Biphenyls as an Inducer of Metabolic Activation Systems. de Serres,
F.J., Fouts, J.R., Bend, J.R. and Philpot, R.M. Eds. In Vitro Metabolic
Activation in Mutagenesis Testing, Elsevier, North-Holland, pp. 85-88
(1976).
(12) Galloway, S.M. et al. Report from Working Group on In Vitro
Tests for Chromosomal Aberrations. Mutation Research 312, 241-261
(1994).
(13) Richardson, C. et al. Analysis of Data from In Vitro
Cytogenetic Assays. Statistical Evaluation of Mutagenicity Test Data.
Kirkland, D.J., Ed. Cambridge University Press, Cambridge, pp. 141-154
(1989).
(14) Soper, K.A. and Galloway S.M. Replicate Flasks are not
Necessary for In Vitro Chromosome Aberration Assays in CHO Cells.
Mutation Research 312, 139-149 (1994).
(15) Krahn, D.F., Barsky, F.C. and McCooey, K.T. CHO/HGPRT Mutation
Assay: Evaluation of Gases and Volatile Liquids. Tice, R.R., Costa,
D.L., Schaich, K.M. Eds. Genotoxic Effects of Airborne Agents. New York,
Plenum, pp. 91-103 (1982).
(16) Zamora, P.O. et al. Evaluation of an Exposure System Using
Cells Grown on Collagen Gels for Detecting Highly Volatile Mutagens in
the CHO/HGPRT Mutation Assay. Environmental Mutagenesis 5, 795-801
(1983).
(17) Locke-Huhle, C. Endoreduplication in Chinese hamster cells
during alpha-radiation induced G2 arrest. Mutation Research 119, 403-413
(1983).
(18) Huang, Y., Change, C. and Trosko, J.E. Aphidicolin--induced
endoreduplication in Chinese hamster cells. Cancer Research 43, 1362-
1364 (1983).
[65 FR 78807, Dec. 15, 2000]